Biostar Pharma Initiates Phase II/III Clinical Trials for Utidelone Capsule Targeting Gastric and Ovarian Cancers

Reuters

09/15

Biostar Pharma Initiates Phase II/III Clinical Trials for Utidelone Capsule Targeting Gastric and Ovarian Cancers

Biostar Pharma, the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd., has announced the initiation of two phase II/III multiregional clinical trials for the Utidelone Capsule (UTD2). The trials focus on the first-line treatment for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma and the treatment for platinum-resistant advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. The first patients were dosed on September 11 and September 12, 2025, respectively. Utidelone is noted for its higher oral bioavailability and lower risk of cross-resistance compared to taxanes, which enhances its convenience and potential in combination therapies. The company has not yet presented results from these ongoing trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beijing Biostar Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN73152) on September 15, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2567119284"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2567119284\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2567119284?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-15 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2567119284","market":"us","top_or_hot":-1,"title":"Biostar Pharma Initiates Phase II/III Clinical Trials for Utidelone Capsule Targeting Gastric and Ovarian Cancers","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Biostar Pharma Initiates Phase II/III Clinical Trials for Utidelone Capsule Targeting Gastric and Ovarian Cancers\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Biostar Pharma, the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd., has announced the initiation of two phase II/III multiregional clinical trials for the Utidelone Capsule (UTD2). The trials focus on the first-line treatment for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma and the treatment for platinum-resistant advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. The first patients were dosed on September 11 and September 12, 2025, respectively. Utidelone is noted for its higher oral bioavailability and lower risk of cross-resistance compared to taxanes, which enhances its convenience and potential in combination therapies. The company has not yet presented results from these ongoing trials.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beijing Biostar Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN73152) on September 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biostar Pharma Initiates Phase II/III Clinical Trials for Utidelone Capsule Targeting Gastric and Ovarian Cancers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiostar Pharma Initiates Phase II/III Clinical Trials for Utidelone Capsule Targeting Gastric and Ovarian Cancers\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-15 20:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Biostar Pharma Initiates Phase II/III Clinical Trials for Utidelone Capsule Targeting Gastric and Ovarian Cancers\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Biostar Pharma, the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd., has announced the initiation of two phase II/III multiregional clinical trials for the Utidelone Capsule (UTD2). The trials focus on the first-line treatment for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma and the treatment for platinum-resistant advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. The first patients were dosed on September 11 and September 12, 2025, respectively. Utidelone is noted for its higher oral bioavailability and lower risk of cross-resistance compared to taxanes, which enhances its convenience and potential in combination therapies. The company has not yet presented results from these ongoing trials.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beijing Biostar Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN73152) on September 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nNDL7sPw5y:1","article_id":"2567119284","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2567119284","pubTimestamp":1757937696,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Biostar Pharma, the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd., has announced the initiation of two phase II/III multiregional clinical trials for the Utidelone Capsule . The trials focus on the first-line treatment for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma and the treatment for platinum-resistant advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. The first patients were dosed on September 11 and September 12, 2025, respectively. Utidelone is noted for its higher oral bioavailability and lower risk of cross-resistance compared to taxanes, which enhances its convenience and potential in combination therapies. The company has not yet presented results from these ongoing trials.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02563":"华昊中天医药-B"},"translate_title":"Biostar Pharma启动Utidelone胶囊靶向胃癌和卵巢癌II/III期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02563":0.9},"content_text":"Biostar Pharma Initiates Phase II/III Clinical Trials for Utidelone Capsule Targeting Gastric and Ovarian Cancers\n    \n\n        Biostar Pharma, the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd., has announced the initiation of two phase II/III multiregional clinical trials for the Utidelone Capsule (UTD2). The trials focus on the first-line treatment for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma and the treatment for platinum-resistant advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. The first patients were dosed on September 11 and September 12, 2025, respectively. Utidelone is noted for its higher oral bioavailability and lower risk of cross-resistance compared to taxanes, which enhances its convenience and potential in combination therapies. The company has not yet presented results from these ongoing trials.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beijing Biostar Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN73152) on September 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}